Vantage MedTech appoints Jim Bartel as new CEO
Vantage MedTech, a leading middle market private equity firm specialising in growth-oriented investments within the healthcare sector, has announced the appointment of Jim Bartel as its new Chief Executive Officer.
Based in Moonachie, New Jersey, and Lenexa, Kansas, Vantage MedTech offers comprehensive design and manufacturing services for medical technologies. The company's clients can leverage the proprietary Advantage Platforms® to accelerate product development timelines.
With over 25 years of experience in medical device and contract manufacturing organisations, Mr. Bartel brings a wealth of knowledge to his new role. He most recently served as CEO and Board Member of Waltek, Inc. and President of Spectralytics, Inc. He also spent four years at Stratasys as VP and General Manager of their rapid prototyping business unit.
Mr. Bartel's expertise extends beyond product development and leadership. He has held roles leading marketing, business development, and sales teams, ensuring a well-rounded approach to his new position at Vantage MedTech. He holds a B.A. in Economics and Management from Hartwick College and an M.B.A. from the University of St. Thomas, Opus College of Business.
Upon his appointment, Mr. Bartel commented on Vantage's growth journey and the dedication of its team of 150+ medical device engineers. Trevor Wahlbrink, Partner at Ampersand Capital Partners, expressed excitement about Mr. Bartel's appointment due to his exceptional leadership qualities and understanding of contract services companies serving the medical device industry.
Ampersand Capital Partners, with offices in Boston, MA, and Amsterdam, Netherlands, has helped build numerous market-leading companies across various healthcare sectors. Vantage MedTech partners with MedTech start-ups and large medical device companies, making it a key player in the industry.
Additional information about Ampersand Capital Partners and Vantage MedTech can be found on their respective websites, Ampersandcapital.com and VantageMedTech.com, as well as on LinkedIn.
While the search results do not explicitly name a new CEO for Vantage MedTech or detail their background in the medical device industry, there is a relevant related executive named John F. Jordon who was the President of Vantage Solutions before it was acquired by Advanco, and he was appointed CEO of Advanco in June 2025. Mr. Jordon has over 35 years of experience in engineering and executive leadership in sectors including pharmaceuticals, with a strong background in serialization technology. This connection suggests he has significant industry experience relevant to medical device and pharma technology, but no direct confirmation that he is the CEO of Vantage MedTech itself is provided.
Regardless, the appointment of Jim Bartel as CEO of Vantage MedTech marks an exciting new chapter for the company, and his extensive experience and leadership qualities are poised to drive the company's continued growth and success in the medical device industry.
- Vantage MedTech, a company known for its services in medical technology, has appointed Jim Bartel as its new CEO, with offices in Moonachie, New Jersey, and Lenexa, Kansas.
- Jim Bartel, with over 25 years of experience in medical device and contract manufacturing organizations, will leverage his expertise in product development and leadership at Vantage MedTech.
- Ampersand Capital Partners, a firm that builds market-leading companies in various healthcare sectors, has played a significant role in Vantage MedTech's growth, making it a key player within the medical device industry.
- The appointment of Jim Bartel is expected to drive continued growth and success for Vantage MedTech, particularly in the areas of finance, business, and medical product development within the medical technology industry.
